The global autoinjectors market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018 at a CAGR of 24.2%. Growth in the autoinjectors market can be attributed to increasing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising prevalence of anaphylaxis, and increasing number of regulatory approvals. However, the preference for alternative routes of drug delivery such as oral diabetic agents and epinephrine nasal sprays is expected to restrain the growth of this market during the forecast period.

Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=173991724

The autoinjectors market is segmented on the basis of therapy, type, end user, and region. On the basis of therapy, the global autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies. The rheumatoid arthritis segment is expected to grow at the highest CAGR during the forecast period owing to the high prevalence of rheumatoid arthritis across the globe.

On the basis type, the market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to account for the largest share of the global autoinjectors market, and is expected to register the highest CAGR during the forecast period. The high growth in the disposable autoinjectors segment can be primarily attributed to their ease of use and the presence of a built-in glass syringe (eliminates the need of manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.

On the basis of end user, the global autoinjectors market is categorized into home care settings and hospital & clinics. The home care settings segment is expected to grow at the highest rate owing to the growth in chronic diseases across the globe and growing demand for self-administering devices.

Geographically, North America is expected to dominate the global autoinjectors market in 2018. The large share of the North American autoinjectors market can primarily be attributed to the rising prevalence of autoimmune and chronic diseases, increasing prevalence of anaphylaxis, and increasing number of FDA approvals in the region.